Scientists identified two ubiquitin ligases, MuRF1 and MAFbx, as key regulators of skeletal muscle atrophy. These proteins are involved in the degradation of muscle proteins, which leads to muscle wasting. The study showed that over-expression of MAFbx in myotubes caused atrophy, while mice deficient in either MAFbx or MuRF1 were resistant to atrophy. These findings suggest that MuRF1 and MAFbx are potential targets for treating muscle atrophy. Muscle atrophy can occur due to various factors such as denervation, injury, immobilization, bed-rest, glucocorticoid treatment, sepsis, cancer, and aging. The balance between protein synthesis and degradation is crucial for maintaining muscle mass. During atrophy, the degradation pathway is favored. While protein degradation systems have been studied, specific molecular mediators of atrophy-related degradation have not been clearly defined. The study used multiple models of muscle atrophy to identify genes that are universally upregulated. Two genes, MuRF1 and MAFbx, were found to be upregulated in all models. These genes are specifically expressed in cardiac and skeletal muscle. Further analysis showed that MAFbx is an SCF-type E3 ubiquitin ligase, which is involved in targeting specific substrates for proteolysis. To determine the role of MAFbx and MuRF1 in muscle atrophy, mice with null alleles for these genes were generated. These mice showed resistance to muscle atrophy, indicating that these proteins are critical for the atrophy process. The study also showed that MAFbx and MuRF1 are involved in the degradation of crucial muscle proteins. The discovery of MuRF1 and MAFbx as markers for muscle atrophy suggests that common pathways are activated by various perturbations. These findings have implications for the development of therapeutic interventions to prevent muscle atrophy in clinical settings.Scientists identified two ubiquitin ligases, MuRF1 and MAFbx, as key regulators of skeletal muscle atrophy. These proteins are involved in the degradation of muscle proteins, which leads to muscle wasting. The study showed that over-expression of MAFbx in myotubes caused atrophy, while mice deficient in either MAFbx or MuRF1 were resistant to atrophy. These findings suggest that MuRF1 and MAFbx are potential targets for treating muscle atrophy. Muscle atrophy can occur due to various factors such as denervation, injury, immobilization, bed-rest, glucocorticoid treatment, sepsis, cancer, and aging. The balance between protein synthesis and degradation is crucial for maintaining muscle mass. During atrophy, the degradation pathway is favored. While protein degradation systems have been studied, specific molecular mediators of atrophy-related degradation have not been clearly defined. The study used multiple models of muscle atrophy to identify genes that are universally upregulated. Two genes, MuRF1 and MAFbx, were found to be upregulated in all models. These genes are specifically expressed in cardiac and skeletal muscle. Further analysis showed that MAFbx is an SCF-type E3 ubiquitin ligase, which is involved in targeting specific substrates for proteolysis. To determine the role of MAFbx and MuRF1 in muscle atrophy, mice with null alleles for these genes were generated. These mice showed resistance to muscle atrophy, indicating that these proteins are critical for the atrophy process. The study also showed that MAFbx and MuRF1 are involved in the degradation of crucial muscle proteins. The discovery of MuRF1 and MAFbx as markers for muscle atrophy suggests that common pathways are activated by various perturbations. These findings have implications for the development of therapeutic interventions to prevent muscle atrophy in clinical settings.